1 Mar 2018 09:00
1 March 2018
Grant of Share Options and PDMR notification
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 1 March 2018, Debra Ainge (Chief Operating Officer of the Company and a PDMR) was granted share options over a total of 17,888 ordinary shares of 0.1 pence each ("Ordinary Shares") under the Clinigen Group Long Term Incentive Plan 2015. These options are nil cost options intended to vest on 16 October 2020 subject to the achievement of certain performance criteria.
The additional share options granted to Debra Ainge relate to the completion of the acquisition of Quantum Pharma plc and her assuming additional responsibility for the early access and 'on demand' access businesses within Unlicensed Medicines.
Director/PDMR | Number of share options granted | Total number of share options now held |
| Total number of ordinary shares now held | Total number of ordinary shares (excluding share options) as % issued share capital |
Debra Ainge | 17,888 | 66,406 |
| 10,254 | 0.01% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person discharging managerial responsibilities.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Debra Ainge | |
2 | Reason for the notification | ||
a) | Position/status | Chief Operating Officer - PDMR | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | N/A | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | Grant of Options | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Exercise Price | No. of shares |
Nil | 17,888 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
17,888 Nil | |
f) | Date of the transaction | 1 March 2018 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
-Ends-
Contact details
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Shaun Chilton, Group Chief Executive Officer | |
Martin Abell, Group Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Tom Ballard (Corporate Broking) | |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas / Jack Wood | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com